Orzax to Go Public: Meeting Investors with R&D and Global Growth Strategy
The initial public offering of Orzax, one of Türkiye's leading dietary supplement manufacturers, has been approved by the Capital Markets Board (SPK). While documents related to the company's IPO were published on the Public Disclosure Platform (KAP), the bookbuilding dates were set as 29-30 June and 1 July 2026.
The Capital Markets Board (CMB) has approved the initial public offering of Orzax, one of Turkey's leading dietary supplement manufacturers. The company's IPO documents have been published on the Public Disclosure Platform (KAP), with subscription periods set for 29–30 June and 1 July 2026.
The IPO, conducted through a consortium led by Info Yatırım, will offer Orzax shares to investors at TRY 69 per share. The company's Borsa Istanbul ticker will be "ORZAX".
As part of the IPO, Orzax plans to increase its paid-in capital from TRY 307 million to TRY 338.5 million. In the total offering, TRY 31.5 million in nominal share capital will be provided through capital increase, while TRY 21 million in nominal value will be offered through secondary offering.
The IPO is expected to achieve a public float of 15.51 percent, with an estimated offering size of approximately TRY 3.6 billion.
Growth Through Production Capacity and R&D Investment
Orzax Chief Executive Officer Yunus Emre Alimoğlu stated that the company aims to strengthen its long-term growth targets through the IPO process.
Alimoğlu, noting that Orzax has operated in the healthcare sector since 2004 and grown through its R&D-focused approach and high quality standards, emphasized that the company has achieved a strong brand position in both the Turkish and international markets through modern production facilities, a broad product portfolio, and quality certifications.
Alimoğlu commented: "With our production capacity and quality standards, we are raising the bar in the sector day by day. Following the IPO, we will focus on creating added value for Turkey and continuing our sustainable growth."
IPO Proceeds to Support New Investments
Orzax aims to use proceeds from the IPO to support new investments, R&D centre development, growth strategies in global markets, and working capital initiatives.
The company intends to increase its capacity for developing innovative products in the healthcare sector and strengthen its presence in international markets.
A Turkish Healthcare Brand Expanding to Global Markets
Operating in the dietary supplement sector, Orzax ranks among Turkey's growing healthcare brands through its production infrastructure, R&D activities, and quality-focused approach.
The company continues its export and international market efforts in line with sustainable growth targets while reaching consumers and healthcare professionals in different geographies with its products.
About Orzax
Founded in 2004, Orzax is a Turkey-based healthcare company operating in the dietary supplement sector. The company continues its product development activities with an R&D, quality and innovation-focused approach; it is sustaining its growth in Turkish and global markets through modern production facilities and a broad product portfolio.
Gallery
